aisencia
aisencia is a Bremen-based health-tech company developing Vistaneos, an integrated LIS/IMS/AI digital pathology platform, and Cutaneos80 AI, serving dermatopathology labs in Germany with expansion into the US, Australia, and general pathology.
- Company typePrivate
- Founded2021
- HeadquartersBremen, Germany
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What aisencia does
aisencia GmbH is a German health-tech company founded in 2021 as a University of Bremen spin-off that develops AI-powered digital pathology software for dermatopathology and, increasingly, general pathology. The company's core platform, Vistaneos, is positioned as the first fully integrated Laboratory Information System (LIS) that natively combines a LIS, an Image Management System (IMS), and an AI diagnostic module (Cutaneos80) within a single browser-based product. Cutaneos80 is a computer vision model that classifies over 50 types of skin lesions and is reported to cover approximately 80% of daily dermatopathology casework; it is currently classified for Research Use Only (RUO). Supporting capabilities include dermatopathology-optimized speech-to-text transcription, structured automated reporting, automated billing, an integrated macro camera, and an active Explainable AI research line (AI-Path) developed with the University of Bremen's Digital Media Lab.
The business model is enterprise software sold primarily on an annual subscription basis, with pricing by quote. GTM combines direct enterprise field sales in Germany (Dermatopathologikum Hamburg is the first confirmed live customer as of October 2025), channel partnerships internationally (PathPresenter for US distribution, Pathscan with Dr. Ian Katz and Paul Richard for Australian entry), and conference-driven demand generation at events such as the ADH Annual Meetings, DMEA, and the Digital Pathology & AI Congress. Revenue streams include Vistaneos LIS licensing (Germany), standalone IMS licensing (international), AI module licensing, and emerging US licensing/royalty flows via PathPresenter. The customer base spans dermatopathology labs, general pathology institutes (via the January 2026 HpH Hamburg development partnership), and, through the May 2026 BESTFIT consortium, head and neck tumor treatment centers pursuing AI-based intraoperative tissue analysis. The company has 1-10 employees, is privately held, GDPR-compliant, and has raised approximately €1M in equity investment options plus €300K in non-dilutive EU grants.
aisencia firmographics
Firmographics- Name
- aisencia
- Legal name
- aisencia GmbH
- Website
- https://aisencia.de
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- aisencia is a Bremen-based health-tech company developing Vistaneos, an integrated LIS/IMS/AI digital pathology platform, and Cutaneos80 AI, serving dermatopathology labs in Germany with expansion into the US, Australia, and general pathology.
- Ownership category
- akta.pro rank
aisencia industry classification
Industry- Product category
- Digital Pathology Software
- NAICS
- Software Publishers (5132)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Medical Imaging AI (HDAAAEAH)
- akta.pro secondary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
Keywords
Where aisencia is headquartered
LocationHeadquarters
- HQ city
- Bremen
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
aisencia business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Vistaneos LIS (Laboratory Information System): Licensing of the Vistaneos Laboratory Information System to dermatopathology and general pathology labs. The product integrates LIS, IMS, and AI in one platform, sold as a bundled or modular solution. The LIS is available for laboratories in Germany, including those without whole-slide scanners, and the IMS is available internationally.
- AI Diagnostic Assistants (DermPath AI / Cutaneos80): AI-powered diagnostic modules (Cutaneos80) integrated into the Vistaneos platform. Currently available for research use only (RUO), with clinical deployment planned. Revenue is generated through integration with the LIS subscription or as standalone AI licensing.
- Image Management System (IMS): The IMS component of Vistaneos is available internationally as a standalone product, enabling laboratories to adopt digital pathology workflows without committing to the full integrated LIS.
- US Market Access via PathPresenter: Through the PathPresenter partnership, aisencia's AI models are made accessible to the US market via PathPresenter's digital pathology platform, potentially generating licensing or commission revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise licensing for dermatopathology labs |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels6 records
aisencia product offering
Product offeringCore offering
aisencia develops and sells an AI-powered digital pathology platform for dermatopathology and general pathology laboratories. Its flagship offering, Vistaneos, integrates a Laboratory Information System (LIS), an Image Management System (IMS), and the Cutaneos80 dermatopathology AI (capable of classifying 50+ skin lesion types covering ~80% of daily cases) into a single browser-based platform with speech-to-text reporting, automated billing, and macro-camera image capture. The IMS is also offered internationally as a standalone product, and the AI models are distributed in the US via the PathPresenter partnership.
Product overview
aisencia offers a unified product portfolio centered on AI-powered digital pathology solutions for dermatopathology. The flagship product is Vistaneos - a fully integrated laboratory information system that combines three core components: a LIS, an image management system (IMS), and the Cutaneos80 AI. This integrated approach enables seamless digital pathology workflows. Cutaneos80 AI, capable of recognizing over 50 skin lesion types (covering ~80% of daily dermatopathology cases), is also available separately for integration with other platforms. The company also offers DigiPath Viewer as part of its product lineup.
Differentiator
Problem solved
Functional benefit
Brands
- Vistaneos: Integrated Laboratory Information System (LIS) and Image Management System (IMS) for dermatopathology with integrated AI capabilities.
- Cutaneos
- DigiPath Viewer
- AI-Path
Products and services
- Vistaneos LIS Fully integrated laboratory information system (LIS) for dermatopathology laboratories that combines LIS, image management system (IMS), and AI (Cutaneos80) in one browser-based platform. Provides speech-to-text transcription, structured automated reporting, automated billing, and integrated macro camera for end-to-end digital pathology workflows.
- Cutaneos80 (DermPath AI) AI-based diagnostic module that classifies over 50 types of skin lesions covering approximately 80% of daily dermatopathology cases. Integrated into Vistaneos or available as standalone AI for other digital pathology platforms. Currently available for research use only (RUO).
- Image Management System (IMS) Standalone Image Management System for digital pathology workflows. Available internationally to laboratories that want to adopt digital pathology image management without the full integrated Vistaneos LIS stack.
- DigiPath Viewer Digital pathology viewer for viewing and analyzing digitized tissue sample images. Part of aisencia's product portfolio for digital dermatopathology workflows.
Quantifiable outcome
- AI covers 80% of daily dermatopathology cases, with ability to recognize and classify over 50 skin lesion types
- +3 more outcomes
Companies that use aisencia
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
aisencia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability9 records
Feature8 records
aisencia partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Fraunhofer MEVIS (Bremen)coreProject partner in the BESTFIT consortium, part of the BMFTR initiative 'AI-supported Precision Surgery in Oncology' (KIOn). Fraunhofer MEVIS contributes expertise in medical image computing for developing AI-based real-time tissue analysis during head and neck tumor surgery.
- Department of Oral and Maxillofacial Surgery, University Medical Center FreiburgcoreClinical partner in the BESTFIT project, contributing expertise in oral and maxillofacial surgery. The project aims to improve therapy planning and treatment of head and neck tumors through AI-based real-time tissue analysis and optimized radiotherapy planning.
- HpH Institute of Pathology and Hematopathology Hamburgcoreaisencia and HpH entered into a comprehensive development partnership to evolve Vistaneos from a dermatopathology-specific LIS into a modern, high-performance, fully integrated LIS for general pathology. The new LIS will natively integrate advanced image processing and AI-powered diagnostic assistants as a true end-to-end solution connecting all functions from sample receipt to billing without media discontinuities.
- PathPresentercoreStrategic partnership with PathPresenter, a global leader in digital pathology solutions, to expand aisencia's offerings to the US market. aisencia's AI models capable of detecting and classifying over 50 types of skin lesions are made accessible through PathPresenter's platform. A preview was showcased at the AAD 2025 meeting in Orlando. The partnership is led by Dr. Rajendra Singh, founder of PathPresenter with over two decades of dermatopathology experience.
- Digital Media Lab, University of BremencoreCollaboration on the AI-Path project to develop the next generation of digital working in pathology. Focus areas include Explainable AI (xAI) for transparent diagnosis suggestions, ergonomic digital workplaces (including VR), and fatigue-avoidance mechanisms for pathologists. Supported by FEI funding of approximately €150,000 through the EFRE-Programm 2021-2027.
Scale indicators8 records
Recent moves7 records
Expansion highlights7 records
aisencia competitors and assessment
Company assessmentEmerging players
- Mindpeak: Hamburg-based AI-for-pathology startup with CE-marked diagnostic AI products, focused on breast cancer (and expanding to other tissues). Same German ecosystem, overlapping customer base of pathology labs, and same AI-on-histopathology category.
- Aignostics: Berlin-based AI pathology spin-out from Charité, focused on AI-based biomarker analysis for biopharma and clinical research. Comparable German DACH AI pathology positioning with broader tissue coverage than aisencia's current dermatopathology focus.
- Lunit: Korean AI company with CE-marked and FDA-cleared AI for tissue analysis (notably Lunit SCOPE for biomarker prediction and Lunit INSIGHT for mammography/ chest). Comparable AI-on-medical-image approach with proven regulatory clearances that aisencia still needs.
Direct peers
- PathAI: US AI pathology company offering both diagnostic AI tools and a digital pathology platform for biopharma and clinical labs. Overlaps with aisencia's AI-on-histopathology positioning and its lab platform ambitions.
- Paige.AI: New York-based AI pathology company with FDA-authorised prostate cancer AI and expanding into dermatopathology. Competes head-to-head with aisencia on AI diagnostic interpretation of histopathology images and platform-centric sales to pathology labs.
- Ibex Medical Analytics: Israel-based AI pathology company with clinically deployed diagnostic AI across multiple cancer types including dermatopathology. Most direct competitor in terms of product category (AI diagnostic assistants for path labs) and go-to-market (enterprise pathology lab sales).
- Proscia: Digital pathology software platform that combines image management, workflow, and AI integrations for pathology labs. Closely comparable to aisencia's Vistaneos in offering an enterprise pathology lab software stack, though broader in target tissue types.
- Owkin: AI-for-pathology and biopharma company offering diagnostic AI models and federated learning on histopathology data. Overlaps with aisencia on AI-driven interpretation of histopathology images and the lab-pharma bridge use case.
Broad incumbents
- Leica Biosystems (Danaher): Established digital pathology incumbent (Aperio GT 450 scanner and Brightfield/ Fluorescent imaging software), now part of Danaher. Represents the broad incumbent pathology imaging and lab IT stack against which aisencia's integrated platform must compete for budget.
Others
- PathPresenter: Global digital pathology viewing and AI-distribution platform run by dermatopathologist Dr. Rajendra Singh. Listed as a strategic distribution partner for aisencia's US entry, but also a potential competitive platform host for rival AI models.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
aisencia social profiles
Digital presenceaisencia compliance and trust
Trust signalCompliance1 record
aisencia financial estimates
Financial estimateRevenue estimate
Valuation estimate
aisencia leadership team
Management profileNumber of profiles
Profiles2 records
aisencia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
aisencia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about aisencia
What does aisencia do?
aisencia develops and sells an AI-powered digital pathology platform for dermatopathology and general pathology laboratories. Its flagship offering, Vistaneos, integrates a Laboratory Information System (LIS), an Image Management System (IMS), and the Cutaneos80 dermatopathology AI (capable of classifying 50+ skin lesion types covering ~80% of daily cases) into a single browser-based platform with speech-to-text reporting, automated billing, and macro-camera image capture. The IMS is also offered internationally as a standalone product, and the AI models are distributed in the US via the PathPresenter partnership.
Is aisencia a public or private company?
aisencia is a private company. It is classified as venture growth investor backed and is currently operating.
When was aisencia founded?
aisencia was founded in 2021. It employs 1 to 10 people.
Where is aisencia based?
aisencia is headquartered in Bremen, Germany, in the Europe region.
How does aisencia make money?
Four revenue lines are on record. Vistaneos LIS (Laboratory Information System) is the primary driver. The others are AI Diagnostic Assistants (DermPath AI / Cutaneos80), image Management System (IMS) and US Market Access via PathPresenter.
Who are aisencia's main competitors?
Emerging players on record are Mindpeak, Aignostics and Lunit. Direct peers are PathAI, Paige.AI, Ibex Medical Analytics, Proscia and Owkin. Leica Biosystems (Danaher) is listed as a broad incumbent. PathPresenter is listed as an others.
Does aisencia have an API?
No public API is recorded for aisencia.
What industry is aisencia in?
aisencia's product category is Digital Pathology Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 5132 and its SIC code is 8000.